Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood metabolites may reveal how severe ARDS will get

NCT ID NCT06036056

Knowledge-focused Sponsor: Sanjay Gandhi Postgraduate Institute of Medical Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 20, 2026 · Last updated Oct 21, 2026 · Updated 1 time

Summary

ARDS is a life-threatening lung condition that requires breathing support. Researchers are using NMR-based metabolomics to compare the metabolic profiles in blood serum from patients with mild, moderate, and severe ARDS against healthy volunteers. The study enrolls 120 critically ill adults with mild ARDS and aims to identify biomarkers that track disease progression and link to the type of infection causing the condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to blood-based biomarkers that help doctors gauge ARDS severity and predict how the condition will progress.
What could go wrong
This is an early observational study with a modest number of patients, so any biomarker patterns may not hold up in larger, more diverse groups or translate into better care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

120 people

The number who actually took part.

Started

Sep 2023

Finished

May 2026

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who fulfill criteria of mild ARDS (PaO2/FiO2 200-300) will be considered for possible inclusion. For comparative analysis, age matched healthy control (from healthy blood donor volunteer will also be included in the study.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Critically ill adult patients having mild ARDS with onset less than 72 hours Exclusion Criteria: * Age less than 18 years or more than 65 years * Expected survival \<72 hours * Refusal from family member

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARDS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute respiratory distress syndrome adult acute respiratory distress syndrome Critical Illness

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARDS

Contacts and locations

Locations

  • Centre of Biomedical Research

    Lucknow, Uttar Pradesh, 226014, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.